This document provides a Czech summary of the 2016 ESC Position Paper on managing cardiovascular toxicity from cancer treatments.
Answers are grounded in this paper and cite their sources.
Facilitates Czech implementation of 2016 ESC cardio-oncology recommendations; extends accessibility of established guidance to non-English clinicians.
No abstract was published with this document — society guidelines, consensus pathways, and scientific statements are typically released without one. See the Key Points and the linked PDF for the full content.
No takes yet. Share an insight, caveat, or question.
Skalická et al. (2017) conducted a review in Cardiovascular toxicity from cancer treatments. Cancer treatments (chemotherapy, targeted therapy, radiotherapy) was evaluated. The 2016 ESC Position Paper provides comprehensive guidelines on the pathophysiology, screening, diagnosis, and management of cardiovascular complications associated with cancer therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: